Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Abstract. To determine the mechanisms whereby HMG‐CoA reductase inhibitors lower the levels of low density lipoproteins (LDL) in patients with mixed hyperlipidaemia. LDL turnover studies were conducted in 12 such patients during placebo and then during treatment with lovastatin. Drug therapy reduced total cholesterol and triglyceride concentrations by 33% and 32%, respectively. During lovastatin therapy, LDL‐cholesterol levels fell by 37%, and LDL‐apo B concentrations decreased by an average of 29%. The decrease in LDL‐apo B concentrations on lovastatin therapy was largely due to an increase in fractional catabolic rates (FCRs) for LDL apo B. The average increase in FCRs was 34%, whereas transport rates (production rates) for LDL apo B remained unchanged. These results strongly suggest that an increase in LDL‐receptor activity is the major mechanism whereby LDL levels are lowered during lovastatin therapy. The data do not indicate that this drug inhibited the input of apo B‐containing lipoproteins, which would have been expected to result in a decrease in the rate of production of LDL. 1991 Blackwell Publishing Ltd

Original languageEnglish (US)
Pages (from-to)341-350
Number of pages10
JournalJournal of Internal Medicine
Issue number4
StatePublished - Oct 1991


  • LDL metabolism
  • lipoprotein kinetics
  • lovastatin
  • mixed hyperlipidaemia

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia'. Together they form a unique fingerprint.

Cite this